Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA to restructure drug review staff

On Friday, FDA unveiled plans to reorganize its review of new drugs. A set of organizational changes, slated to take effect in the spring of 2005,

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE